CITIUS ONCOLOGY, INC. 8-K

What Happened Citius Oncology, Inc. (NASDAQ: CTOR) filed a Form 8-K on March 31, 2026 to report that it issued a press release providing a commercial update on the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl). The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: March 31, 2026 (Form 8-K, Item 8.01 — Other Events).
• Product: LYMPHIR™ (denileukin diftitox-cxdl) — commercial update on its U.S. launch.
• Press release included as Exhibit 99.1; cover page interactive data also filed in iXBRL (Exhibit 104).
• The 8-K did not present financial statements or quarterly/earnings data in the filing.

Why It Matters A commercial update on a product launch is a direct operational news item that investors track for progress toward market availability and potential future revenue. While this 8-K does not report revenues or earnings, the update signals management activity around LYMPHIR’s U.S. commercialization — information useful to investors monitoring product adoption, launch milestones, or subsequent financial disclosures.